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The dinuclear zinc complex [Zn2{bcmp(-H)}(μ-Cl)](ClO4)2·
H2O {bcmp = 2,6-bis(1,4,7-triazacyclonon-1-ylmethyl)-4-
methylphenol} has been synthesized and structurally charac-
terized. The DNA binding affinity was assessed by ethidium
bromide fluorescence quenching experiments. The complex
relaxes supercoiled pUC19 DNA into the nicked form at low
micromolar concentration. Mechanistic studies were carried
out using the DNA and RNA models bis(2,4-dinitrophenyl)
phosphate (BDNPP) and 2-hydroxypropyl p-nitrophenyl
Introduction
Despite the great success of platinum-based drugs in an-
ticancer chemotherapy with cisplatin, oxaliplatin and car-
boplatin being in routine clinical use,[1] severe side effects, a
high general toxicity and inherent and acquired resistance
are major limitations.[2] Recently, complexes of endogenous
transition metal ions such as Cu and Zn attract significant
interest as potential new cancer therapeutic agents.[3] How-
ever, despite the variety of physiological roles of the Zn2+
ion[4] and the wide repertoire of ZnII complexes as DNA
binding agents,[5] photosensitizers in tumour therapy, radio-
protective,[6] antidiabetic insulin-mimetic[7] and antibacte-
rial or antimicrobicial agents,[8] very few data on the cytoto-
xicity of zinc-based compounds against human cancer cell
lines have been reported.[9]
Zinc is an essential metal in most living organisms and
it is found in the active site of many metalloenzymes. It
plays an important role in biological hydrolysis reactions
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phosphate (HPNP). A detailed kinetic analysis suggested
that the bridging OH group of the solution species
[Zn2{bcmp(-H)}(μ-OH)]2+ acts as the nucleophile in the hy-
drolysis of BDNPP, while in the case of HPNP, the bridging
OH group acts as a general base and seems to shift to a ter-
minal position upon substrate coordination. Finally, the cyto-
toxicity profile of the dinuclear zinc(II) complex was as-
sessed. The complex showed promising in vitro antitumour
activity against pancreatic and lung cancers cell lines.
and examples of hydrolytically active zinc enzymes include
P1 nuclease,[10] alkaline phosphatase,[11] phospholipase
C,[12] and aminopeptidase.[13] The catalytic role of zinc in
these enzymes includes Lewis acid activation of the sub-
strate and the formation of Zn–OH which can act as an
efficient nucleophile or as a general base catalyst at physio-
logical pH. The high catalytic efficiency of dizinc enzymes
has been attributed to the synergistic action of the two
metal ions[14] and has inspired the design and study of a
large number of bimetallic Zn complexes as potential cleav-
ing agents for nucleic acids and phosphate esters as their
models.[15–17] In particular, dinuclear zinc complexes with
bis(1,4,7-triazacyclonon-1-yl) ligands [bis(tacn)] are of con-
siderable interest due to their often remarkable reactivity
towards phosphodiesters. A range of ligands with the two
aza-crown rings separated by spacers of different length,
rigidity and geometry have been studied to date.[18–21] The
dinuclear zinc complex of 1,3-bis(1,4,7-triazacyclonon-1-
yl)-2-hydroxypropane reported by Morrow et al. is one of
the best dinuclear catalysts for the transesterification of the
RNA model compound 2-hydroxypropyl p-nitrophenyl
phosphate (HPNP).[22] Scrimin et al. attached two tacn
units to a heptapeptide. Upon addition of Zn2+ plasmid
DNA was cleaved with a rate constant of 1.010–5 s–1 un-
der physiological conditions.[23a] Very recently, the same
group attached Zn tacn moieties to the surface of gold
nanoparticles to obtain a nanosystem that provides the
www.eurjic.org FULL PAPER
highest kcat value for the cleavage of HPNP ever reported
in water.[23b]
Here we report the dinuclear zinc complex of the
bis(tacn) ligand 2,6-bis(1,4,7-triazacyclonon-1-ylmethyl)-4-
methylphenol (bcmp), its interaction with DNA, bis(2,4-di-
nitrophenyl) phosphate (BDNPP) and HPNP as well as its
cytotoxicity towards a panel of human tumour cell lines.
Results and Discussion
Ligand Design and Synthesis
It is well established that Zn2+ ions bind with unusually
high affinity to ligands containing the nine-membered aza-
crown binding site 1,4,7-triazacyclononane. The logK value
for mononuclear Zn(tacn)2+ is 11.3,[24] suggesting that the
bis(tacn) ligand bcmp can form a highly stable Zn complex
under physiological conditions. The aromatic spacer pro-
vides a rigid scaffold for the bimetallic site, while the bridg-
ing phenoxy group shields the electrostatic repulsion be-
tween the metal ions and holds the two Zn2+ ions in close
proximity.
Bcmp (4) that has been previously reported[25] was syn-
thesized as depicted in Scheme 1. In contrast to the litera-
ture procedure, Boc was used to protect two of the three
secondary amine nitrogens of tacn. This route was chosen
over the original procedure using tosyl protecting groups
because of the less time-consuming work-up and fewer pu-
rification steps required. The protected ligand 3 was synthe-
sized by reacting 2,6-bis(chloromethyl)-4-methylphenol
with two equivalents of tacn-(Boc)2 (2). Deprotection of the
amine with trifluoroacetic acid afforded 4 as a yellow oil
which is soluble in methanol and water at alkaline pH.
Scheme 1. Synthetic route for the synthesis of the Zn complex. i)
BOC-ON, CHCl3; ii) THF/CHCl3; iii) TFA/CH2Cl2/Et2O; iv)
Zn(ClO4)2.
Synthesis and Characterization of the Dizinc Complex
The dinuclear zinc complex [Zn2{bcmp(-H)}(μ-Cl)]-
(ClO4)2 (5) was prepared by reacting 4 with two equivalents
zinc salt in methanol/water at pH 6–7. X-ray suitable crys-
Eur. J. Inorg. Chem. 2014, 4084–4092 © 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim4085
tals of 5·H2O were obtained by slow evaporation of an
aqueous solution of 5.
The X-ray structure of 5·H2O is shown in Figure 1, se-
lected bond lengths and angles are listed in Table 1. The
asymmetric unit of 5·H2O contains the complex cation with
a bridging chlorido ligand, two perchlorate anions and one
water molecule of crystallization. Each Zn centre adopts a
distorted square-pyramidal coordination geometry with the
tertiary nitrogen, one secondary amine nitrogen, the bridg-
ing chloride and phenolate oxygen defining the basal plane,
while the apical site is occupied by the other secondary
amine nitrogen. The τ value which indicates the degree of
trigonal distortion from an ideal square-pyramidal coordi-
nation geometry is 0.269 for Zn(1) and 0.114 for for Zn(2).
According to the definition by Addison [τ = (α-β)/60 where
α and β are the two largest bond angles] an ideal square
pyramid has a τ value of 0, while τ is 1 for a trigonal bi-
pyramid.[26] The Zn ions are displaced by 0.416(1) [Zn(1)]
and 0.280(1) Å [Zn(2)] from the basal plane in the direction
of the apical nitrogen. The two apical nitrogens are anti
to each other. The bridging phenolate oxygen and chlorido
ligand hold the two Zn ions at a distance of 3.219(1) Å, the
Zn–Ophenolate–Zn and Zn–Cl–Zn angles are 107.2(1) and
85.65(3)°, respectively. The Zn2OCl unit in 5·H2O is essen-
tially planar [maximum deviation from the best weighted
plane 0.0147(9) Å for O(1)]. The dihedral angle between the
Figure 1. (a) View of the cation of [Zn2{bcmp(-H)}(μ-Cl)](ClO4)2·
H2O (5·H2O) with the atom numbering scheme. Thermal ellipsoids
are drawn at the 40% level. (b) Crystal packing of 5·H2O.
Hydrogen atoms have been omitted for clarity.
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Zn2OCl plane and the bridging phenyl ring is 36.4(1)°. An
interesting feature of the crystal structure of 5·H2O is the
packing of the complex cations and water molecules of
crystallization in the crystal lattice (Figure 1, b). The com-
plex cations are located around threefold screw axes with
the methyl groups pointing inwards while hydrogen-bond-
ing interactions between the water molecules generate hex-
agonal water clusters. In addition to donating a H bond to
a neighbouring water molecule, each water acts as a H bond
donor to a perchlorate oxygen so that each hexagon of
water molecules is surrounded by six perchlorate anions.
Further hydrogen bonding within the lattice is observed be-
tween amine nitrogens and perchlorate oxygens. Geometric
parameters of the H bonding interactions in 5·H2O are
given in Table 1.
Table 1. Selected bond lengths [Å], angles [°] and hydrogen bonding
interactions in compound 5·H2O.
Zn1–N1 2.099(3) Zn2–N4 2.116(3)
Zn1–N2 2.131(3) Zn2–N5 2.088(3)
Zn1–N3 2.065(3) Zn2–N6 2.082(3)
Zn1–O1 2.011(2) Zn2–O1 1.988(2)
Zn1–Cl1 2.3472(9) Zn2–Cl1 2.3883(9)
Zn1···Zn2 3.219(1)
N1–Zn1–N2 83.41(11) N4–Zn2–N5 84.09(12)
N1–Zn1–N3 86.49(11) N4–Zn2–N6 85.49(11)
N2–Zn1–N3 84.27(12) N5–Zn2–N6 85.39(11)
N1–Zn1–Cl1 149.70(8) N4–Zn2–Cl1 161.61(8)
N2–Zn1–O1 165.85(11) N5–Zn2–O1 168.47(11)
Zn1–Cl1–Zn2 85.65(3) Zn1–O1–Zn2 107.21(10)
Hydrogen-bonding interactions
D–H···A[a] d(D···A) (DHA)
N2–H2N···O3#1 3.292(5) 152
N2–H2N···O5#1 3.091(6) 130
N3–H3N···O8 2.944(5) 163
O1Wb···O1W[b], #2 2.84(1)
O1Wb···O4#1 3.18(2)
O1Wb···O1W[b],#1 2.87(1)
O1Wb···O4#2 2.97(1)
[a] Symmetry operation: #1: –x + y, 1 – x, z; #2: y – 1, y – x,
1 – z. [b] Site occupancy 0.5 (cf. experimental section).
The stability of the dinuclear Zn complex in aqueous
solution has been investigated by 1H NMR spectroscopy
(Figure S1 in the Supporting Information). The CH2 pro-
tons of the tacn rings that give a triplet around 2.7 ppm in
the free ligand (D2O, pD 11) split into three broadened sig-
nals at δ = 2.89, 2.60 and 2.50 ppm. No changes in the
1H NMR spectrum are observed between pD 3.6 and 11.0
indicating that the Zn ions remain bound to the ligand over
this pD range. At pD  3.6 the 1H NMR spectrum be-
comes more complicated and new resonances appear in the
region of the ring methylene protons suggesting partial
dissociation and formation of the mononuclear Zn com-
plex.
Due to the lability of the Zn–Cl bond, the spontaneous
substitution of (bridging) chlorido ligands by water in aque-
ous solution is well established for zinc complexes[27–30] and
the species [Zn2{bcmp(-H)}(OH)(ClO4)]+ was identified in
the ESI MS spectrum of 5 in water (signal centred at m/z
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= 637.11; Figure S2 in the Supporting Information). The
potentiometric titration of the Zn complex revealed a single
deprotonation step with a pKa value of 5.370.15 (Figure
S3 in the Supporting Information). Although clearly at the
low end of the pKa range for a water molecule bridging two
Zn ions,[31–33] this value can be assigned to the formation
of the hydroxo-bridged dizinc species.
[Zn2{bcmp(-H)}(μ-H2O)]3+ + OH– i [Zn2{bcmp(-H)}(μ-OH)]2+ +
H2O
Relatively low pKa values for the formation of hydroxo-
bridged metal complexes that indicate strong binding of the
hydroxide ion to the metal ions are not unprecedented. For
example, a pKa of 4.4 has been reported for the bridging
water in the dinuclear nickel complex [Ni2(H2O)4(bdpz)]4+
{bdpz = 1,4-bis(2,2-dipyridyl-methyl) phthalazine}.[34]
DNA Interaction
The ability of the zinc complex to bind to CT-DNA was
studied by evaluating the fluorescence emission intensity of
the ethidium bromide (EB)-DNA system upon the addition
of different amounts of the dinuclear ZnII compound.[35]
The fluorescence intensity of EB-DNA decreases rapidly
with increasing concentrations of the complex. Results de-
picted in Figure 2 underlined that the dinuclear ZnII com-
plex efficiently quenched the fluorescence emission of EB.
Notably, the fluorescence quenching constant evaluated
using the Stern–Volmer equation was 0.91 (cf. experimental
section), thus indicating that the complex strongly binds to
DNA. A DNA-binding metal complex can quench the EB
emission by either competing with EB for binding sites or
by accepting the excited state photon. It is unlikely that the
Zn complex can compete with EB for intercalative binding
sites and groove binding seems more likely.
Figure 2. DNA binding and cleavage. A. Stern–Volmer quenching
plot of [Zn2{bcmp(-H)}(μ-Cl)](ClO4)2. B. Agarose gel electrophore-
sis patterns of SC pUC19 DNA incubated with complex 5 in Tris
buffer at 37 °C for 3 h. Lane 1, DNA control; lane 2, DNA + 5
(5 μm); lane 3, DNA + 5 (10 μm); lane 4, DNA + 5 (25 μm); lane
5, DNA + 5 (50 μm).
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The cleavage ability of the dinuclear ZnII complex was
measured from the conversion of the SC form (form I) of
plasmid pUC19 DNA to the nicked-circular form (NC,
form II). SC pUC19 DNA (1 μg/mL) was incubated with
increasing complex concentrations (range 5–50 μm) for 3 h.
As depicted in Figure 2 (b), treatment with the dinuclear
ZnII complex resulted in a concentration dependent cleav-
age of DNA. Interestingly, the bimetallic compound was
able to convert SC-DNA into the NC form even at 10 μm
concentration (lane 3), and complete DNA cleavage (ab-
sence of the SC conformation) occurred at 50 μm (lane 5).
Phosphate Diester Hydrolysis
In order to identify the catalytically active species that
hydrolyses the phosphate diester linkages in DNA, kinetic
experiments have been carried out with the activated sub-
strate bis(2,4-dinitrophenyl) phosphate (BDNPP). The 5-
mediated cleavage of the activated RNA model compound
2-hydroxypropyl-4-nitrophenyl phosphate (HPNP) was also
studied. The hydrolysis reactions were monitored by follow-
ing the increase in the visible absorbance at 400 nm because
of the release of 2,4-dinitrophenolate and 4-nitrophenolate,
respectively.
BDNPP Hydrolysis
The dependence of the reaction rate of BDNPP cleavage
on the pH value in the presence of 5 was studied over the
pH range 3.5–9.5. The plot of the pseudo-first-order rate
constants vs. pH revealed a sigmoidal curve (see Figures 3
and S4). A non-linear least-squares fit of the data gave a
kinetic pKa value of 5.40.1.
Figure 3. Rate-pH profile for the cleavage of BDNPP (510–5 m;
) and HPNP (510–5 m; ) in the presence of 5 (1 mm) at 40 °C.
[buffer] = 50 mm [buffer = PIPBS (pH 3.5–5), MES (pH 5–6.7),
HEPES (pH 6.8–8.5), and CHES (pH 8.5–11.0)]; I = 0.1 m (KNO3).
Figure 4 shows the dependence of the hydrolysis rate on
the concentration of the zinc complex (pH 8.0, 40 °C). At
low concentration the rate constant increases linearly, while
at concentrations 3 mm a gradual deviation from linearity
is apparent. A linear fit of the data in the 0.25–3 mm range
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gave an apparent second-order rate constant of 0.028 m s–1
for low metal complex concentrations. The fact that the
curve tends to flatten at higher concentration suggests weak
binding between BDNPP and 5.
Figure 4. Dependence of the cleavage rate of BDNPP (510–5 m)
on the concentration of 5 at pH 8.0 (50 mm HEPES) and 40 °C. I
= 0.1 m (KNO3). The solid line shows the linear fit of the data
using the first 8 data points.
The kinetic pKa value obtained from the rate-pH profile
of 5-mediated BDNPP hydrolysis is in good agreement with
the thermodynamic pKa value (5.37) and suggests that the
bridging hydroxide acts as the reactive species, either as a
nucleophile or a general base. To gain more insight into the
reaction mechanism, the solvent deuterium isotope effect
kH/kD was measured. The solvent deuterium isotope effect
is the classical method for distinguishing between a nucleo-
philic and a general base mechanism. Generally, a kH/kD
value ranging from 0.8 to 1.5 indicates a nucleophilic
mechanism for phosphate ester hydrolysis, where no proton
transfer is involved in the rate-determining step, while a kH/
kD value greater than 2 supports a general base mechanism,
where M–OH deprotonates an external nucleophile.[38] The
average kH/kD value obtained at different pL values (L =
H, D) for the hydrolysis of BDNPP in the presence of 5 is
1.29 (Figure S5 and Table S1) suggesting a direct nucleo-
philic attack of the bridging OH group to the phosphorus.
This mechanism is not unprecedented for dizinc com-
plexes.[36,37] By contrast, the hydrolysis of BDNPP com-
plexes of type FeIII(μ-OH)MII and FeIII(μ-CH3COO)2MII
(M = Zn, Cu, Mn, Fe) that have been extensively studied
by Neves, Schenk and co-workers proceeds via a mecha-
nism that involves monodentate coordination to the di-
valent metal ion followed by intramolecular attack of a ter-
minally FeIII-bound hydroxide.[39–42] It was concluded that
the μ-OH was a poorer nucleophile than the terminal OH.
BDNPP hydrolysis by a dinuclear CuII(μ-OH)CuII complex
of a Schiff base ligand related to bcmp, 6-amino-6-methyl-
perhydro-1,4-diazepine (AAZ), has recently been
studied.[43,44] DFT calculations on the complex-BDNPP ad-
duct supported a reaction mechanism in which the bridging
hydroxide acts as the nucleophile towards the phosphorus
of the monodentally coordinated BDNPP as suggested for
5.
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HPNP Cleavage
As shown in Scheme 2, the uncatalyzed cleavage of RNA
and HPNP proceeds via the intramolecular nucleophilic at-
tack by the C-2 hydroxy group resulting in the formation
of the 2,3-cyclic phosphate diester.[45]
Scheme 2. Transesterification of HPNP following intramolecular
nucleophilic attack.
The rate-pH profile of the 5-mediated cleavage of HPNP
is depicted in Figures 3 and S6. Again, a sigmoidal curve
was obtained. However, fitting the data gave a kinetic pKa
value of pH 7.80.1 which indicates that the active species
for cleaving HPNP is different from that in BDNPP hydrol-
ysis (see discussion below). The plot of the initial rate v0 vs.
complex concentration (Figure 5) revealed saturation kinet-
ics and the linear Lineweaver–Burk plot (Figure S7) indi-
cated Michaelis–Menten behaviour with the formation of a
kinetically active complex-substrate intermediate. From the
Lineweaver–Burk plot, the hydrolysis rate of the bound sub-
strate, kcat = 2.6010–4 s–1, and the substrate binding con-
stant, 1/Km = 206 m–1, were obtained. These values indicate
a good catalytic activity in comparison with other dinuclear
Zn complexes[46–48] and a moderate binding affinity of
HPNP for 5. However, 5 is approximately 2 and 3 orders of
magnitude less reactive than the two most efficient Zn cata-
lysts reported by Mareque-Rivas and Williams (kcat =
0.017 s–1; pH 7.4, 25 °C) and Scrimin et al. (kcat = 0.196 s–1;
pH 7.5, 40 °C) for the same substrate.[23,49] The rate-pH
profile suggests an active species with a pKa value of about
8. A pKa value in this range can be attributed to a water
or alcohol terminally bound to zinc[32] and the following
mechanisms are consistent with the kinetic pKa: (i) A ter-
minal Zn–OH group acts as a general base and depro-
tonates the C2–OH group of HPNP. Intramolecular attack
of the deprotonated C2–OH group gives the cyclic phos-
phate ester and (ii) Zn coordinates to the C2–OH group
and thus activates the nucleophile.
Again, reaction rates were measured in D2O to distin-
guish between nucleophile activation and a general base
mechanism. kH/kD was determined to be 2.64 indicating a
general base mechanism with the formation of the C2
oxoanion in the rate-determining step. Potentiometric ti-
tration of 5 revealed a single deprotonation step so that
[Zn2{bcmp(-H)}(μ-H2O)]3+ and [Zn2{bcmp(-H)}(μ-OH)]2+
must be the only species present under the conditions of
the kinetic study. There is no indication of any titratable
terminally bound water molecule with a pKa value in the
region of the kinetic pKa. Thus, a mechanism that is consis-
tent with the rate-pH profile would involve a shift of the μ-
OH group into a terminal position upon substrate coordi-
nation as shown in Scheme 3. Unfortunately, we cannnot
Eur. J. Inorg. Chem. 2014, 4084–4092 © 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim4088
Figure 5. Dependence of the transesterification rate of HPNP
(510–5 m) on the concentration of 5 at pH 8.5 (50 mm HEPES)
and 40 °C; I = 0.1 m (KNO3).
distinguish between a mono- and bidentate coordination
mode of the phosphate diester, as all attempts to co-crystal-
lise the Zn complex with a hydrolytically stable phosphate
diester were unsuccessful. It should be noted that a shift of
a bridging OH group to a terminal position or at least an
elongation of one of the bridging bonds upon substrate co-
ordination is discussed for dinuclear hydrolytically active
Zn enzymes.[50]
Scheme 3. Possible reaction mechanisms for the transesterification
of HPNP by 5.
To unambiguously identify the cleavage product, the re-
action of 5 with HPNP was monitored by 1H and 31P NMR
spectroscopy. The time-dependent 31P NMR spectra of
HPNP (2.010–2 m) in the presence of 0.1 equiv. of 5 in
95% CD3OD/5% D2O are shown in Figure S8. The 31P
NMR signal at δ = 18.7 ppm that increases with time con-
firms the formation of the 2,3-cyclic phosphate diester as
the cleavage product. After 48 h, 1.410–2 m cyclophos-
phate has formed. Thus, the NMR experiments also suggest
that 5 can act as a true catalyst.
Cytotoxic Activity
The cytotoxic properties of 5 were evaluated against a
panel of human tumour cell lines containing examples of
colorectal (HCT-15), pancreatic (BxPC3), cervical (A431),
breast (MCF-7), lung (A549), and ovarian (2008) cancers.
For comparison purposes, the cytotoxicity of cisplatin, the
most widely used metal-based anticancer drug, was evalu-
ated under the same experimental conditions. IC50 values,
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calculated from the dose vs. survival curves obtained after
72 h of drug treatment from the MTT test, are shown in
Table 2.
Table 2. Cytotoxic activity of 5 and cisplatin towards human cancer
cell lines.
Cell lines IC50, [μm]SD [a]
cisplatin [Zn2{bcmp(-H)}(μ-Cl)](ClO4)2
HCT-15 11.321.51 56.578.23
BxPC3 11.132.36 12.522.43
A431 1.650.51 42.414.06
MCF-7 7.600.21 56.475.98
A549 9.982.86 10.813.01
2008 2.221.03 49.346.78
[a] Cells (3–8104 ml–1) were treated for 72 h with increasing con-
centrations of [Zn2{bcmp(-H)}(μ-Cl)](ClO4)2 or cisplatin. Cell via-
bility was evaluated by means of MTT test. IC50 values were calcu-
lated by the dose-response curves by means of four parameter logis-
tic model (p  0.05); SD = standard deviation.
Although the cytotoxic activity was significantly lower
than that of cisplatin against four of the tested tumor cell
lines, the dimetallic ZnII complex retained a surprising in
vitro antitumor activity against BxPC3 and A549 cancer
cells. Notably, the IC50 values calculated for 5 in pancreatic
BxPC3 and in “non small cells” lung cancer cells were com-
parable to those elicited by the reference metallo-drug cis-
platin. These data highlight for 5 a particular activity
against pancreatic and lung cancer cell histotypes.
Conclusions
[Zn2{bcmp(-H)}(μ-OH)]2+ acts as a DNA binding and
cleavage agent. It hydrolyzes the DNA model BDNPP by
a mechanism involving nucleophilic attack by the bridging
hydroxide. By contrast, a general base mechanism with a
shift of the μ-OH group into a terminal position is hypothe-
sized for the cleavage of the RNA model HPNP.
Finally, the dinuclear zinc(II) complex exhibits in vitro
antitumour activity against pancreatic and lung cancer cells.
Experimental Section
Materials and General Methods: Disodium N,N,N-tritosyldi-
ethylenetriamide, Zn(ClO4)2·6H2O, and NaClO4 were purchased
from Aldrich and used as supplied. 1,2-bis(tosyloxy)ethane was
purchased from TCI Europe and used as supplied. All the other
chemicals and solvents were of analytical or spectroscopic grade,
obtained from commercial sources and used without further purifi-
cation. Deuterated solvents were obtained from Apollo Scientific.
N,N,N-Tris(p-tolylsulfonyl)-1,4,7-triazacyclononane [tacn-
(Ts)3],[51] di-tert-butyl 1,4,7-triazacyclononane-1,4-dicarboxylate
[tacn-(Boc)2],[52] 2,6-bis(chloromethyl)-4-methylphenol,[53] bis(2,4-
dinitrophenyl) phosphate (BDNPP)[54] and the sodium salt of 2-
hydroxypropyl p-nitrophenyl phosphate (HPNP)[55] were prepared
following the literature procedures. 1,4,7-Triazacyclononane (tacn)
was synthesized according to a modified literature procedure (Sup-
porting Information).[56]
1H and 31P NMR spectra were recorded on a Jeol EXC-400 spec-
trometer and referenced to TMS or the solvent residual peak as
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internal and 85% H3PO4 as external reference. The pD values of
D2O solutions were measured by use of a glass electrode and ad-
dition of a value of 0.4 to the pH meter reading.[57,58] The pD
values were adjusted using concentrated DNO3 and NaOD solu-
tions. UV/Vis measurements were carried out on a Varian Cary 50
scan spectrophotometer coupled to a Grant thermostatted water
circulation bath. Elemental analyses (carbon, hydrogen and nitro-
gen) were performed with a Perkin–Elmer 2400 series II analyzer.
ESI Mass Spectra were recorded with Waters LCT Premier XE
Spectrometer.
2,6-Bis(1,4,7-triazacyclonon-1-ylmethyl)-4-methylphenol (bcmp, 4):
tacn-(Boc)2 (3.83 g, 11.6 mmol) and triethylamine (2.34 g,
22.3 mmol) were dissolved in 30 mL of dry THF. 2,6-bis(chlorome-
thyl)-4-methylphenol (1.19 g, 5.8 mmol), dissolved in 30 mL of dry
THF, was added dropwise at 0 °C over a period of 1 h. A white
solid formed immediately and the suspension was stirred for 20 h
at 0 °C. The white solid (Et3NHCl) was filtered off and the filtrate
was evaporated to dryness by rotary evaporation. The resulting pale
yellow powder was purified by column chromatography using pe-
troleum ether/ethyl acetate (5:1) as eluent. 3.55 g of Boc protected
bcmp (3) were obtained (4.5 mmol, 77%). 1H NMR (CDCl3): δ =
6.85 (s, 2 H, Har); 3.72 (s, 4 H, CH2); 3.46 (m, 8 H, CH2, tacn);
3.30 (m, 8 H, CH2, tacn); 2.69 (m, 8 H, CH2, tacn); 2.18 (s, 3 H,
CH3); 1.48 [s, 18 H, CH3(tBu)]; 1.45 [s, 9 H, CH3(tBu)]; 1.43 [s, 9
H, CH3(tBu)]. 3 was subsequently dissolved in 10 mL of CH2Cl2.
A mixture of CF3COOH/CH2Cl2 (27 mL/27 mL) was added drop-
wise at 0 °C and the mixture was stirred for 1 h. The solvent was
removed by rotary evaporation. The residue was treated with di-
ethyl ether (20 mL) and dried again by rotary evaporation to re-
move residual trifluoroacetic acid. After repeating this procedure
three times a yellow solid (4·nCF3CO2 H) was obtained. 1H NMR
(CD3OD): δ = 7.03 (s, 2 H, Har); 3.94 (s, 4 H, CH2); 3.06 (m, 8 H,
CH2, tacn); 2.76 (m, 8 H, CH2, tacn); 2.64 (m, 8 H, CH2, tacn);
2.20 (s, 3 H, CH3). 4·nCF3CO2H was dissolved in 50 mL of meth-
anol and 200 mL of water. The solution was cooled to 0 °C and
the pH was adjusted to 9 with NaOH. The neutral ligand 4 was
extracted with 3 75 mL of CHCl3, washed with brine and dried
with Na2SO4 which was filtered off. Evaporation of the filtrate to
dryness gave 4 as a yellow oil, yield 1.57 g (46%). 1H NMR
(CDCl3): δ = 6.80 (s, 2 H, Har); 3.72 (s, 4 H, CH2); 3.70 (br. s, 1
H, OH); 2.68 (m, 24 H, CH2, tacn); 2.19 (s, 3 H, CH3). ESI-MS:
m/z 391.31 [M + H]+.
[Zn2{bcmp(-H)}(μ-Cl)](ClO4)2 (5): The Zn complex was obtained
by mixing an aqueous solution (10 mL) of Zn(ClO4)2·6H2O
(400 mg, 1.07 mmol) and a methanolic solution (5 mL) of bcmp
(209 mg, 0.54 mmol) and adjusting the pH to 6.2 with NaOH. The
transparent, clear solution was evaporated on a rotavapor. The resi-
due was dissolved in 12 mL of methanol and filtered. Slow dif-
fusion of diethyl ether into the alcoholic solution afforded colour-
less crystals of formula [Zn2{bcmp(-H)(μ-Cl)](ClO4)2, yield 310 mg
(0.42 mmol, 73%). Anal. Calcd. (%) for C21H37Cl3N6O9Zn2: C,
33.42; H, 4.95; N, 11.13; found C, 33.54, H, 4.90; N, 10.86. 1H
NMR (D2O, pD 6.8): δ = 6.87 (s, 2 H, Har); 3.78 (s, 4 H, CH2);
2.89 (br. m, 6 H, CH2, tacn); 2.60 (br. m, 12 H, CH2, tacn); 2.50
(m, br., 6 H, CH2, tacn); 2.04 (s, 3 H, CH3). ESI-MS: m/z 633.11
[[Zn2{bcmp(-H)}(μ-OH)](ClO4)]+.
Crystals of 5·H2O suitable for X-ray analysis were obtained by slow
evaporation (4 weeks) of an aqueous solution (5 mL) of 20 mg of
the complex. The presence of the chlorido ligand is most likely due
to the contamination of the ligand with chloride during the work-
up. Washing the neutral ligand with brine led to batches containing
sizeable amounts of the hydrochloride.
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Caution! Although no problems were encountered in this work,
transition metal perchlorate complexes are potentially explosive
and should be handled with proper precautions.
Potentiometric Titration: An aqueous solution of 5 (1 mm, 100 mL)
was titrated with a standardized 0.1 m NaOH solution at 25 °C.
The ionic strength was maintained at 0.1 m with KNO3. pH values
were measured with a Jenway 3510 pH meter fitted with a Refex
Sensor Ltd. EC-1910-11 glass electrode. The program HYPER-
QUAD was used to calculate the deprotonation constant from the
titration data.[59]
UV Kinetic Measurements: The hydrolysis rates of BDNPP and
HPNP were measured by monitoring the increase in the visible
absorbance at 400 nm due to the release of the 2,4-dinitrophenolate
and 4-nitrophenolate anions. Rate constants were obtained by the
initial rate method ( 5% conversion). Concentrations of 2,4-di-
nitrophenolate and 4-nitrophenolate were calculated from the ex-
tinction coefficients (12100 and 18700 m–1 cm–1 for 2,4-dinitrophen-
olate and 4-nitrophenolate, respectively). Concentrations were cor-
rected for the degree of ionization of 2,4-dinitrophenol and 4-nitro-
phenol at the respective pH value using pKa (2,4-dinitrophenol) =
4.0[60] and pKa (4-nitrophenol) = 7.15.[61] In a typical experiment
15 μL of a freshly prepared BDNPP or HPNP stock solution (5 mm
in DMSO and H2O, respectively) were added to a solution of the
metal complex (1.5 mL, 0.25–5 mm) at 40 °C. The metal complex
solutions were buffered with 50 mm PIPBS (pH 3.5–5), MES (pH
5–6.7), HEPES (pH 6.8–8.5) and CHES (pH 8.5–11.0). The ionic
strength was maintained at 0.1 m with KNO3. Cleavage rates for
BDNPP and HPNP have been corrected for the spontaneous hy-
drolysis of the substrates.[54] The kinetic pKa values were deter-
mined by fitting the data to
kobs = (kH2O[H+] + kOHKa)/(Ka + [H+]).
To determine the solvent deuterium isotope effect, analogous ki-
netic experiments were performed in 99.9% D2O. The correction
pD = pHmeasured + 0.4 was applied to the pH meter readings.[57,58]
Kinetic runs were run in duplicate to give a reproducibility of
15%.
NMR Kinetic Measurements: The transesterification rate of HPNP
in methanol was measured by monitoring the increase of the inten-
sities of the 31P and 1H NMR peaks of the cleavage products with
respect to the HPNP signals. The experiments were conducted in
CD3OD/D2O (95:5). The substrate concentration was 20 mm. The
ratio between HPNP and the Zn complex was 10:1 in all experi-
ments.
X-ray Analysis: Crystal data of 5·H2O were collected at room tem-
perature on an Oxford Diffraction Xcalibur CCD diffractometer
using graphite-monochromated Mo-Kα radiation (λ =
0.71069 Å).[62] The structure was solved by direct methods and sub-
sequent Fourier syntheses and refined by full-matrix least-squares
on F2 using SHELXS-97, SHELXL-97[63] and Oscail.[64] The scat-
tering factors were those given in the SHELXL program. Hydrogen
atoms except those of the water molecule of crystallization were
generated geometrically and refined as riding atoms with isotropic
displacement factors equivalent to 1.2 times those of the atom to
which they were attached (1.5 for methyl groups). The water mole-
cule of crystallization is disordered over two positions having site
occupancy factors of 0.5. Each of the disordered water molecules is
part of a hexagon of symmetry-related H-bonded water molecules.
Graphics were produced with ORTEX.[65] Crystallographic data
and details of refinement are reported in Table 3.
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Table 3. Crystallographic data for compound 5·H2O.
Formula C21H39Cl3N6O10Zn2
Mr 772.67
Crystal colour and habit colourless block
Crystal size 0.300.250.22
Crystal system trigonal
Space group R3¯
a /Å 35.407(1)
b /Å 35.407(1)
c /Å 12.9018(4)
V /Å3 14007.3(9)
Z 18
Dcalc /g cm–3 1.649
μ(Mo-Kα) /mm–1 1.858
F(000) 7164
2θ range /° 6.1–50.7
Measured reflections 9865
Unique reflections (Rint) 5707 (2.3%)
Observed reflections 4552 [I2σ(I)]
Parameters 379
Final R1, wR2 [I2σ(I)][a] 3.8%, 10.2%
Final R1, wR2 (all data)[a] 5.5%, 11.2%
Goodness-of-fit 1.037
(observed reflections)
[a] R1 = Σ||Fo| – |Fc||/Σ|Fo|; wR2 = [Σw(Fo2 – Fc2)2/Σw(Fo2)2] 1/2; w–1
= σ2(Fo2) + (aP)2; P = (Fo2 + 2Fc2)/3.
CCDC-920702 contains the supplementary crystallographic data
for this paper. These data can be obtained free of charge from The
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/
data_request/cif.
DNA Interaction: Fluorescence Quenching Experiments: The influ-
ence of the addition of increasing concentrations of compound 5
to the DNA–ethidium bromide (EB) complex solution composed
of 10 μm CT-DNA (8.0–15 kbp) and 0.33 μm EB in Tris buffer solu-
tion, has been obtained by recording the variation of the fluores-
cence emission spectra. The fluorescence spectrum of the solution
was obtained by exciting at 520 nm and measuring the emission
spectrum at 587 nm. The quenching efficiency for 5 was evaluated
according to the classical Stern–Volmer equation:
F0/F = 1 + KSVr
where F0 is the emission intensity in the absence of quencher, F is
the emission intensity in the presence of quencher, KSV is the Stern–
Volmer constant, and r is the concentration ratio of the complex
to DNA. KSV constant was determined from the slope of the plot
of F0/F vs. r.
pUC19 DNA Cleavage Activity: The DNA cleavage ability of com-
pound 5 was evaluated by agarose gel electrophoresis. DNA plas-
mid pUC19 (2686 bp) at concentration 1 μg/μL was incubated with
increasing concentration (range 5–50 μm) of 5 in Tris buffer (50 mm
Tris, 18 mm NaCl, pH 8.2) at 37 °C for 3 h in the dark. The reaction
was quenched by the addition of 3 μL of loading buffer (0.25%
bromophenol blue and 30% glycerol), and samples were loaded
onto a 1% agarose gel in TBE buffer (89 mm Tris, 89 mm boric
acid, 2 mm EDTA, pH 8.2). The gels were subjected to electropho-
resis for 4 h at 50 V, followed by staining with 0.5 μg/mL EB over-
night. Gel bands were visualized using a UV transilluminator and
photographed using an Olympus® digital camera.
Experiments with Cultured Human Cells: Compound 5 was dis-
solved in DMSO just before the experiment, and a calculated
amount of drug solution was added to the cell growth medium to
a final solvent concentration of 0.5%, which had no detectable ef-
fect on cell killing. Cisplatin was dissolved in 0.9% sodium chloride
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solution. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazol-
ium bromide] and cisplatin were obtained from Sigma Chemical
Co, St. Louis, USA.
Cell Cultures: Human lung (A549), breast (MCF-7), colon (HCT-
15), and pancreatic (BxPC3) carcinoma cell lines were obtained
from American Type Culture Collection (ATCC, Rockville, MD).
Human ovarian cancer cell lines 2008 were kindly provided by Prof.
G. Marverti (Dept. of Biomedical Science of Modena University,
Italy). Human cervical carcinoma cells A431 were kindly provided
by Prof. F. Zunino (Division of Experimental Oncology B, Istituto
Nazionale dei Tumori, Milan, Italy). LoVo human colon-carci-
noma cell line were kindly provided by Prof. F. Majone (Depart-
ment of Biology of Padova University, Italy). Cell lines were main-
tained in the logarithmic phase at 37 °C in a 5% carbon dioxide
atmosphere using the following culture media containing 10% fetal
calf serum (Euroclone, Milan, Italy), antibiotics (50 units/mL peni-
cillin and 50 μg/mL streptomycin), and 2 mm l-glutamine: (i)
RPMI-1640 medium (Euroclone) for MCF-7, HCT-15, A431, 2008
and BxPC3 cells; (ii) F-12 HAMS (Sigma Chemical Co.) for LoVo
and A549 cells.
MTT Assay: The growth inhibitory effect toward tumor cells was
evaluated by means of MTT assay.[66] Briefly, (3–8)103 cells/well,
dependent upon the growth characteristics of the cell line, were
seeded in 96-well microplates in growth medium (100 μL). After
24 h, the medium was removed and replaced with fresh media con-
taining the compound to be studied at the appropriate concentra-
tion. Triplicate cultures were established for each treatment. After
72 h, each well was treated with 10 μL of a 5 mg/mL MTT saline
solution, and following 5 h of incubation, 100 μL of a sodium do-
decylsulfate (SDS) solution in HCl 0.01 m was added. After an
overnight incubation, cell growth inhibition was detected by meas-
uring the absorbance of each well at 570 nm using a Bio-Rad 680
microplate reader. Mean absorbance for each drug dose was ex-
pressed as a percentage of the control untreated well absorbance
and plotted vs. drug concentration. IC50 values, the drug concentra-
tions that reduce the mean absorbance at 570 nm to 50% of those
in the untreated control wells, were calculated by four parameter
logistic (4-PL) model.
Supporting Information (see footnote on the first page of this arti-
cle): Synthetic procedure for compound 1, 1H and 31P NMR spec-
tra.
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